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Abstract
Background: Endorepellin, the C-terminal domain V of the heparan sulfate proteoglycan perlecan,
exhibits powerful and targeted anti-angiogenic activity on endothelial cells. To identify proteins
involved with endorepellin anti-angiogenic action, we performed an extensive comparative
proteomic analysis between vehicle- and endorepellin-treated human endothelial cells.
Results: Proteomic analysis of endorepellin influence on human umbilical vein endothelial cells
identified five differentially expressed proteins, three of which (β-actin, calreticulin, and chaperonin/
Hsp60) were down-regulated and two of which (vimentin and the β subunit of prolyl 4-hydroxylase
also known as protein disulfide isomerase) were up-regulated in response to endorepellin
treatment—and associated with a fold change (endorepellin/control) ≤ 0.75 and ≥ 2.00, and a
statistically significant p-value as determined by Student's t test.
Conclusion: The proteins identified represent potential target areas involved with endorepellin
anti-angiogenic mechanism of action. Further elucidation as such will ultimately provide useful in
utilizing endorepellin as an anti-angiogenic therapy in humans.
Background
Perlecan is a modular proteoglycan which is strategically
located in basement membranes and cell surfaces and is
capable of regulating the bioactivity of various growth fac-
tors and key receptors involved in angiogenesis and growth
control [1-11]. In general, perlecan, as a whole molecule,
supports vascular growth in vivo [12-15] and is pro-ang-
iogenic both in vitro and in vivo [16-20]. In agreement with
these studies, the anti-angiogenic fragment of anti-
thrombin down-regulates the expression of perlecan in
endothelial cells [21,22]. In contrast, the C-terminal mod-
ule of perlecan, named endorepellin to designate its anti-
endothelial activity, is anti-angiogenic in a dominant nega-
tive fashion [23,24]. Our previous studies have shown that
endorepellin, by uniquely interacting with the α2β1
integrin, a key receptor in the angiogenesis process [25-29],
signals endothelial cells to halt their migratory and capil-
lary morphogenesis ability [24,30]. We have discovered
that endorepellin specifically targets the tumor endothe-
lium, inhibiting tumor blood vessel development and con-
sequently tumor growth [31]. The anti-angiogenic
signalling network evoked by a short exposure of endothe-
lial cells to recombinant human endorepellin has been par-
tially characterized at the molecular level. Following a
specific interaction with the α2β1 integrin, endorepellin
evokes a signalling cascade that includes activation of
cAMP-dependent protein kinase A, sustained activation of
focal adhesion kinase and transient increases in the phos-
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phorylation of p38 MAPK and Hsp27 [24]. This signalling
culminates into the marked disassembly of the actin
cytoskeleton and focal adhesion complexes, resulting in the
inhibition of endothelial cell migration [24].
The present study was designed to identify target genes
affected by treatment of primary endothelial cell cultures
with endorepellin. Our ultimate goal was to uncover how
the endothelial cell global proteome is reprogrammed to
counteract endorepellin-evoked angiostatic signals. Pro-
tein profile analysis of vehicle- versus endorepellin-
treated endothelial cells identified five differentially
expressed proteins of interest, of which three were down-
regulated and two were up-regulated, in response to
endorepellin treatment. The proteins identified, which
include proteins already known to be involved in the ang-
iogenic process such as calreticulin/vasostatin, actin and
protein disulfide isomerase, represent potential targets
involved in endorepellin anti-angiogenic mechanism of
action.
Results and Discussion
To identify proteins involved with endorepellin angi-
ostatic action, we performed an extensive comparative
proteomic analysis between vehicle- and endorepellin-
treated endothelial cell proteomes. Each recombinant
endorepellin batch was tested for positive biological activ-
ity utilizing a highly sensitive actin disassembly assay
[24], and protein response was analyzed following 2 h,
500 nM endorepellin treatment. We selected the 2 hour
treatment period for this particular study to reflect global
changes in endothelial cell protein synthesis affected
downstream in the endorepellin signaling pathway. One
hundred and six protein spots were positively identified in
our HUVEC 2-D protein profiles. All identified proteins
were categorized into one of six functional groups (Figure
1 and Additional file 1) with the majority of proteins
functionally classified as signal transduction and mem-
brane-associated (34%) or cytoskeletal and cell motility-
related (20%). The remaining were classified as metabolic
or various proteins (15%, each) and as chaperone or pro-
teolytic proteins (12 and 4%, respectively).
We focused our analysis on the majority of endothelial
cell proteins within the pI 4 – 7 range and utilized 8–18%
gradient gels to achieve separation of the proteins in the
second dimension. Protein spots were detected by the
highly sensitive colloidal blue stain which can detect < 10
ng of protein. Comparative proteomic analysis identified
five distinct proteins with differential expression levels in
response to endorepellin treatment (Figure 2 and Table
1). All five spots were associated with a fold change
(endorepellin/control) ≤ 0.75 and ≥ 2.00, and a p-value
~< 0.1 (considered statistically significant). Fold changes
were calculated by the formula 10^ (log-scale mean
Classification of the 106 protein spots positively identified  during the HUVEC proteome analysis Figure 1
Classification of the 106 protein spots positively iden-
tified during the HUVEC proteome analysis. All pro-
teins identified were categorized into one of six functional 
groups. Please see Additional file 1 – Description and sum-
mary of the proteins identified in the comparative pro-
teome's of HUVEC control and endorepellin-treated, for a 
complete listing and further information regarding the pro-
teins corresponding to each group.
Comparative proteomic analysis of vehicle- and endorepellin- treated human endothelial cells Figure 2
Comparative proteomic analysis of vehicle- and 
endorepellin-treated human endothelial cells. Repre-
sentative 2-D protein profiles from vehicle- and endorepellin-
treated endothelial cells are depicted with protein separation 
according to isoelectric point (pI, x-axis) and molecular weight 
(kDa, y-axis). Encircled protein spots correspond to the five 
proteins differentially expressed in response to endorepellin 
treatment. Compare calreticulin (1), β-actin (2), chaperonin/
Hsp60 (3), vimentin (4) and prolyl 4-hydorxylase, β subunit (5), 
spot intensities in the two sets of samples. The spots under 
the bracket represent serum albumin by LC-MS/MS.Proteome Science 2008, 6:7 http://www.proteomesci.com/content/6/1/7
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Endorepellin – log-scale mean Control). Statistical analy-
sis of protein expression data was completed through
missing value imputation via K-nearest neighbors (KNN,
K = 10) analysis accounting for gel-to-gel variability
[32,33], followed by log-transformation of the imputed
data and comparison of experimental data with statistical
validation by Student's t test.
In response to endorepellin treatment, three spots were
significantly down-regulated (fold change ≤ 0.75), one
spot was significantly up-regulated (fold change ≥ 2.00)
and one spot was completely absent from the control
(Table 1). The five spots were identified by Electrospray
LC-MS/MS analysis as calreticulin, β-actin, chaperonin/
Hsp60 (Figure 2, spot numbers 1–3, respectively), vimen-
tin (spot no. 4) and prolyl 4-hydroxylase, β subunit (spot
no. 5). Notably, all five proteins identified have been
functionally linked to the α2β1 integrin and/or associated
with angiogenesis. Therefore each protein may contribute
to the molecular basis of endorepellin anti-angiogenic
mechanism of action on the endothelium.
β-actin
Endothelial cell migration and adhesion depend on
cytoskeletal remodeling mediated by actin dynamics
[34,35]. Cell migration has been associated with β-actin
mRNA localization and increased actin synthesis [36,37].
Angiogenesis inhibitors, such as endostatin and endore-
pellin, target endothelial cell migration by interfering
with actin organization[24,38-40].
Endorepellin was found to decrease the protein levels of
endothelial cell actin (Figures 2 and 3A). In additional
experiments, the continuous exposure to endorepellin
(200 nM) resulted in a decline of endothelial cell β-actin
levels with a T1/2 of ~45 minutes (Figure 3C and 3D). The
observed changes in actin may reflect endorepellin action
through the α2β1 integrin [24]. Previously, we identified
α2β1 integrin as the major receptor for endorepellin on
endothelial cells, and associated the interaction with pro-
moting endothelial cell disassembly of the actin cytoskel-
eton and focal adhesion complexes. The observed
decrease in actin may be directly related to the breakdown
of the cellular actin network which would interfere with
endothelial cell migration and capillary morphogenesis.
Calreticulin
One of the key proteins identified in our proteomics anal-
ysis and validated by immunoblotting, was calreticulin
(Figure 3A and 3B), a multifunctional and widespread cal-
cium-binding protein found in the endoplasmic reticu-
lum, but also at the cell surface and as a secreted form
[41]. Additionally, vasostatin, a fragment of calreticulin,
inhibits angiogenesis and tumor growth [42,43]. The
localization of calreticulin in other cellular compartments
has prompted reconsideration of this protein as a media-
tor of a broader array of cellular functions.
Notably, calreticulin is essential for integrin-mediated cal-
cium signalling and adhesion [44], and interacts with
α2β1 on the surface of platelets [45], Jurkat and PC3 cells
[46,47]. Calreticulin can regulate adhesion by a number
of mechanisms. For example, calreticulin modulates the
Table 1: Differential expression of endothelial cell proteins evoked by exposure to recombinant human endorepellin
Spot number 
(see Fig. 2)
Protein ID Gene 
name
NCBI 
Accession 
Number
Mr (kDa) pI Response to 
endorepellin 
(mean fold 
change)
p-value Reported functionsa
1 Calreticulin CALR 4757900 48 4.14 ↓ Downregulated, 
0.642
0.0881 Molecular calcium binding and 
chaperone protein
2 β-actin ACTB 4501885 42 5.18 ↓ Downregulated, 
0.403
0.0023 Cellular structure, motility and 
integrity
3 Chaperonin/
Hsp60
HSPD1 31542947 61 5.59 ↓ Downregulated, 
0.714
0.1262 Mitochondrial protein assembly, 
prevention of misfolding, 
produced under stress within 
the mitochondrial matrix
4 Vimentin VIM 4507895 54 4.91 ↑ Upregulated, 
3.178
0.0276 Class III intermediate filament, 
cytoskeletal crosstalk, 
intracellular communication, 
influence cell shape, adhesion 
and migration, signalling events
5 Prolyl 4-
hydroxylase, 
β subunit
P4HB 20070125 57 4.61 ↑ Absent from 
Controlb
- Key subunit of prolyl 4-
hydroxylase enzyme, identical to 
protein disulfide isomerase
aAs reported in the protein database on the ExPASy web server and in the NCBI Entrez Protein database.
bTrace amounts of this enzyme were found by immunoblotting (see Figure 3 E)Proteome Science 2008, 6:7 http://www.proteomesci.com/content/6/1/7
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affinity of α2β1 integrin for its ligands via transient inter-
actions with the cytoplasmic domain of the integrin α2
subunit [48]. The transient interaction is believed to func-
tion during the formation of a primary pro-adhesive cel-
lular complex but may not be required during the later
establishment of a full focal adhesion [46,49]. Consistent
with this, calreticulin-deficient cells have impaired cell
adhesion [44], whereas cells overexpressing calreticulin
have increased levels of vinculin and are consequently
more adhesive [50]. Thus, a possible contributing factor
to the anti-adhesive properties of endorepellin would be
reducing intracellular calreticulin levels.
Calreticulin regulation by endorepellin must also be con-
sidered beyond the subcellular levels and extend to the
cell surface. Cell surface calreticulin, in contrast to intrac-
ellular calreticulin, actually counters cell adhesion. The
extracellular matrix thrombospondin proteins function
through cell surface calreticulin to promote focal adhe-
sion disassembly and ultimately favor cell migration [51-
53]. Our proteomics study was not capable of distinguish-
ing between cell surface and intracellular calreticulin.
Additionally an endorepellin—cell surface-calreticulin
functional and cooperative interaction has not been inves-
tigated. The potential for the observed endorepellin-
induced downregulation of calreticulin to represent
changes in either cell surface or intracellular calreticulin
levels alone versus overall total levels is intriguing to con-
sider within the context of endothelial cell adhesion,
migration and endorepellin function.
Chaperonin/Hsp60
We found that endorepellin treatment reduced endothe-
lial expression levels of chaperonin/Hsp60. The heat
shock protein family member chaperonin (heat shock
protein 60-kDa or mitochondrial matrix protein P1) func-
tions primarily in cooperation with Hsp10 to aide in
mitochondrial protein folding, unfolding and degrada-
tion events [54]. Numerous other functions have been
attributed to chaperonin/Hsp60 outside of its role as a
classical heat shock protein, including α3β1-specific
Immunoblotting supports the proteomic analysis and indicates relative changes of various endothelial cell proteins evoked by  endorepellin treatment Figure 3
Immunoblotting supports the proteomic analysis and indicates relative changes of various endothelial cell pro-
teins evoked by endorepellin treatment. (A) Close up view of two representative 2-D gels, depicting the decline in calre-
ticulin and β-actin levels. Notice that the major actin isoforms also show reduced staining intensity in response to endorepellin 
treatment. (B) Immunoblotting of control and endorepellin-treated endothelial cell lysates using an antibody against human cal-
reticulin. Equal amounts of total proteins were loaded. (C) Immunoblot analysis of β-actin levels following treatment with ~200 
nM endorepellin for the designated time intervals. (D) The kinetic data for β-actin expression levels were derived from immu-
noblotting data as presented in C. Essentially HUVEC β-actin expression levels were examined by Western blot following 
exposure to endorepellin for the indicated time points. β-actin levels were quantified over similar amounts of protein loading 
and graphed as percent β-actin levels (based upon time point 0) versus exposure to endorepellin treatment (hours). The data 
were graphed in SigmaPlot v9 and fit by non-linear regression analysis. Each data point represents the mean ± S.E.M. from three 
experiments. The T1/2 of ~45 min. represents the time to reduce β-actin levels by 50% as compared to the control. (E) Immu-
noblot analysis of vimentin and prolyl 4-hydroxylase, β subunit protein levels following endorepellin treatment for the indicated 
time points. GAPDH is shown as loading control. All verification experiments presented in panels C-E utilized new samples of 
endorepellin-treated HUVEC lysates, separate from those used in proteomic analysis.Proteome Science 2008, 6:7 http://www.proteomesci.com/content/6/1/7
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integrin activation and influencing apoptotic cell death
[54,55].
While the observed down-regulation could presumably
disturb the endothelial cell mitochondrial stress response,
perhaps the decreased expression may promote apoptosis
in these cells. Indeed, attenuated expression of Hsp60 by
antisense mediated knockdown in cardiac myocytes has
been associated with promoting apoptosis [56]. Addition-
ally the PPARγ agonist, PGJ2(15-deoxy-Δ12–14-prostaglan-
din J2) has pro-apoptotic effects on human vascular
endothelial cells that has been associated with a decrease
in Hsp60 expression [57]. Intriguingly, endothelial cells
during apoptotic death release into their media a frag-
ment of endorepellin which could act in a paracrine fash-
ion on adjacent cells [58]. The exact apoptotic role of
chaperonin/Hsp60 may be a complex and variable one
[56,59,60], but it is intriguing to consider in light of the
anti-angiogenic influence of endorepellin on the endothe-
lium.
Vimentin
Vimentin is a type-III intermediate filament of the cellular
cytoskeleton. Intermediate filaments form a cage-like net-
work throughout the entire cell, which links intermediate
filaments to cytoskeletal crosstalk among microfilaments,
microtubules, and mediates signaling events from one
region of the cell to another [61]. Vimentin intermediate
filaments are capable of influencing cell shape, cell adhe-
sion and migration and cell signaling events.
Notably, the α2β1 integrin interacts with vimentin and
co-localizes with the integrin in endothelial cell focal
adhesions and contributes to the vimentin-associated
matrix adhesion structures identified in endothelial cells
[62,63]. Given these roles, a decreased expression of
vimentin protein levels might be predicted to support
anti-angiogenic action. Unexpectedly, our studies found
that endorepellin increased vimentin protein levels (Table
I and Figure 3E). Increased expression of vimentin may
negatively contribute to the dynamics of cytoskeletal rear-
rangement induced by endorepellin action or may repre-
sent an increase in vimentin cleavage products as a result
of apoptosis. Indeed, vimentin is a substrate for caspase
cleavage. Cleavage produces vimentin fragments that
inhibit continued intermediate filament assembly, and
results in the breakdown of the intermediate filament
cytoskeletal network—hallmarks of apoptotic cell death
[64].
Prolyl 4-hydroxylase, β subunit
Collagen biosynthesis requires the enzyme prolyl 4-
hydroxylase, which catalyzes the formation of 4-hydroxy-
proline [65]. Hydroxylation at these residues is a key fac-
tor in facilitating collagen triple helix assembly and
stability. Prolyl 4-hydroxylase is a tetramer composed of
two α and two β subunits, with the β subunit being iden-
tical to protein disulfide isomerase [66,67]. Protein
disulfide isomerase possesses an enzymatic role, catalyz-
ing protein disulfide bond formation and a chaperone
role, promoting proper protein folding [68-70]. In the
proteomics analysis, endothelial cells did not show any
detectable levels of the enzyme by using Colloidal blue in
contrast to the endorepellin-treated cells (Figure 2). How-
ever by immunoblotting using an antibody specific for the
β subunit we were able to detect low levels of the enzyme
and these levels were markedly upregulated by endorepel-
lin (Figure 3E). The immunoblotting data further indicate
a sustained induction of the enzyme with kinetics similar
to those shown for vimentin (Figure 3E).
We believe the observed increase in the P4-H β subunit
may be related to the protein's inherent dual roles. Enzy-
matically active prolyl 4-hydroxylase requires the β subu-
nit for proper tetramer formation, folding and to prevent
aggregation of the α subunits [71]. The increase in β sub-
units could potentially promote the formation of the
active enzyme, essentially favor collagen biosynthesis and
eventual deposition into the extracellular matrix. Endore-
pellin may induce prolyl 4-hydroxylase levels as a means
to support extracellular matrix assembly and counter ang-
iogenesis since the matrix serves as a barrier to migrating
endothelial cells.
The β subunit in the α2β2 tetramer as well as monomer
form is equivalent to protein disulfide isomerase and both
possess disulfide isomerase activity. The endorepellin-
evoked increase in β subunit monomers may actually be
an increase in the chaperone functioning protein disulfide
isomerase. Since proper protein folding by chaperones is
essential to protein synthesis, we believe that the endore-
pellin-evoked increase in β subunits/protein disulfide iso-
merase levels may link anti-angiogenic endorepellin to
interfering with protein synthesis. Of note, tumstatin, the
anti-angiogenic fragment of type IV collagen, inhibits
endothelial cell protein synthesis and results in apoptotic
cell death [72,73].
Conclusion
Comparative assessment of vehicle- and endorepellin-
treated primary endothelial cells identified five proteins
with differential expression patterns in response to
endorepellin. The identification of these endothelial cell
proteins, which are directly or indirectly related to the
α2β1 integrin and angiogenic processes, provides new
insight into the molecular and cellular biology of
endorepellin anti-angiogenic network by representing
potential target areas involved with endorepellin action.
Understanding the basis for endorepellin targeted action
on the endothelium, by identifying new proteins andProteome Science 2008, 6:7 http://www.proteomesci.com/content/6/1/7
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links to new pathways, may ultimately provide useful in
utilizing endorepellin as an anti-angiogenic therapy in
humans.
Methods
Protein extraction from human umbilical vein endothelial 
cells and quantification
2 × 106 human umbilical vein endothelial cells (VEC
Technologies, Inc.) were cultured to confluence in M131
endothelial cell growth factor-supplemented media.
Endothelial cells were either treated with 500 nM
endorepellin-supplemented media (experimental, n = 5)
or PBS-supplemented media (control, n = 5) for 2 hours.
Cell cultures were gently washed in Hank's balanced salt
solution (with Ca+2/Mg+2) and protein was extracted by
total cell lysis in 4% CHAPS; 8 M urea lysis buffer. Cell
lysates were collected via gentle scraping, centrifuged at
15,000 RPM for 10 minutes at 4°C, and followed by
mild sonication over ice. Protein was quantified using
the 2-D Quant Kit (GE Healthcare), collected and stored
at -80°C.
Two-dimensional (2-D) gel electrophoresis
Forty μg of total protein lysate from control (n = 5) and
endorepellin-treated (n = 5) endothelial cells were each
suspended in lysis buffer (4% CHAPS; 8 M urea), 1 M
DTT, IPG buffer pH 4–7 and a trace of bromophenol blue
at a final volume of 350 μl. Sample mixtures were centri-
fuged at 14,000 RPM for 15 minutes. Protein samples
were separated in the first dimension on 18 cm IPG strips
pH 4–7 using an IPG phor (GE Healthcare) with active
rehydration at 30 V for 12 h followed by focusing at 500
V for 1 h, 1000 V for 1 h and 8000 V for 6 h. Prior to pro-
tein separation in the second dimension, the IPG strips
were equilibrated for fifteen minutes with gentle agitation
at room temperature in equilibration buffer (20% glyc-
erol, 2% SDS, 0.375 M Tris/HCl pH 8.8, 6 mol/L urea)
containing 13 mM DTT followed by equilibration buffer
containing 2.5% iodoacetamide. IPG strips were then
directly applied to 8–18% SDS Tris-Glycine gels (Jule Inc.
Biotechnologies), and protein separation in the second
dimension was performed using the DALT6 platform (GE
Healthcare) at 2 W/gel for thirty minutes, followed by 20
W/gel until completion. 2-D gels were stained with the
protein sensitive Colloidal Blue Staining Kit according to
the manufacturer's protocol and stored in ultrapure water
at 4°C (Invitrogen Life Technologies). Each gel image was
recorded by the Typhoon fluorescent imager and the
Image Quant software program (GE Healthcare).
Protein profile analysis and mass spectrometry
To compare proteins differentially expressed in control
and endorepellin-treated samples, each of the ten gel 2-D
images was analyzed in the DIA program of the DeCyder
v5.01 software package (GE Healthcare). The DIA pro-
gram compares protein expression profiles by assessing
and quantifying the intensity of the protein spots identi-
fied in each gel. Each of the ten DIA analysis files were col-
lected and analyzed together in the DeCyder BVA
program. The BVA program identified reproducible spots
of interest in control and endorepellin-treated HUVEC
proteomes. These protein spots of interest were extracted
from the gel and trypsin digested by the Ettan Dalt spot
handling work station (GE Healthcare) in preparation for
protein identification by Electrospray LC-MS/MS analysis
(Finnigan Proteome X LTQ). Sequence analysis was per-
formed with the BioWorks Browser v3.2 software package
using, XCorr, ΔCn (>0.1), RSp (<4) and probability values
(<1), as filters for positive protein identification.
Differential protein expression data analysis and 
statistical validation
Statistical analysis of protein expression data was com-
pleted through missing value imputation via K-nearest
neighbors (KNN, K = 10) analysis as previously described
[32,33], followed by log-transformation of the imputed
data and comparison of control and endorepellin-treated
values with statistical validation by Student's t  test (p-
value ~< 0.1, considered statistically significant). Fold
changes were calculated by the formula 10^(log-scale
mean endorepellin – log-scale mean control). Proteins
were categorized according to protein expression, down-
regulated (fold change ≤ 0.75) or up-regulated (fold
change ≥ 2), in response to endorepellin treatment.
Immunoblotting endothelial cell protein lysates
Endothelial cells were endorepellin treated as described
above. Cell lysates were collected in RIPA buffer, sepa-
rated by SDS-PAGE and transferred to Nitrocellulose (Bio-
rad). Immunoblotting was performed with polyclonal
anti-calreticulin (Stressgen, SPA-600); monoclonal anti-β-
actin (Sigma, A 5316); monoclonal anti-vimentin (Sigma,
V 6630) and monoclonal anti-prolyl-4-hydroxylase β
(ImmunO, 63164). Primary antibodies were detected
with donkey anti-rabbit HRP (GE Healthcare) or goat
anti-mouse HRP (Pierce) secondary antibodies, and
developed by ECL (Pierce).
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